



September 18, 2024

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Symbol: LUPIN**

**Scrip Code: Equity - 500257**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

**Dear Sir/Madam,**

We are pleased to enclose a Press Release as regards, the Company having entered into non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in the Indian market.

The above may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The same is for your information and dissemination.

Thanking you,

**FOR LUPIN LIMITED**

**AMIT KUMAR GUPTA  
COMPANY SECRETARY & COMPLIANCE OFFICER  
(ACS -15754)**

**Encl: a/a.**

**LUPIN LIMITED**

**Registered Office:** 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India

**Mumbai, September 18, 2024:** Global pharma major Lupin Limited (Lupin) today announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin's Lupivon® and will be available in two strengths - 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

"We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," said, **Rajeev Sibal, President India Region Formulations, Lupin.**

Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India<sup>1</sup>. While prevalence of GERD ranges from 5% to 28.5%<sup>2</sup>, PUD has prevalence in the range of ~ 8%<sup>1</sup>. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption<sup>3</sup>.

### About Vonoprazan

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough, and meal-independent dosing.<sup>4</sup>

In India, Vonoprazan is approved by the DCGI for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment.

### About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit [www.lupin.com](http://www.lupin.com) or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

**For further information or queries please contact –**

**Rajalakshmi Azariah**

Vice President & Global Head – Corporate Communications, Lupin

[rajalakshmiазariah@lupin.com](mailto:rajalakshmiазariah@lupin.com)

#### **References**

<sup>1</sup> [Clinical profiling of patients with Acid Peptic Disorders \(APD\) in India: a cross-sectional survey of clinicians](#)

<sup>2</sup> <https://link.springer.com/article/10.1007/s12664-020-01104-0>

<sup>3</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140167/>

<sup>4</sup> [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/215151s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215151s000lbl.pdf)